BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ASRT: Updated Q4 Results Puts 2023 in Focus

ASRT: ASEG Guideline a Significant Positive, PT to $8

ASRT: Convertible Offering Pauses Momentum

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>ASRT has setup 2023 with the potential for growth even though Cambia now has generic competition. ASRT had been mentioning the generic competition for more than a year.</li>
<li>Looking ahead to 2023, ASRT should benefit from having samples of Otrextup available for physicians.</li>
<li>Indocin remains the primary revenue generator for ASRT. We are expecting greater revenue contribution from Indocin to offset Cambia</li>
</ul>


ASRT has setup 2023 with the potential for growth even though Cambia now has generic competition. ASRT had been mentioning the generic competition for more than a year.
Looking ahead to 2023, ASRT should benefit from having samples of Otrextup available for physicians.
Indocin remains the primary revenue generator for ASRT. We are expecting greater revenue contribution from Indocin to offset Cambia


Assertio Holdings

ASRT: Looking Ahead to 2023